INF904 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

Read More

5 minute read

Pharma Industry News

InflaRx prepares for key INF904 Phase 2a topline readout in chronic skin inflammation trials

Find out how InflaRx’s INF904 topline Phase 2a data could redefine treatment for hidradenitis suppurativa and chronic spontaneous urticaria.

bySoujanya Ravi

November 8, 2025

web analytics